

# Head and Neck Cancer Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_ **Stage:** \_\_\_\_\_

**Line of Therapy:**  Neoadjuvant/Pre-Op  Adjuvant/Post-Op **ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

1<sup>st</sup> Line  2<sup>nd</sup> Line

## Non-Nasopharyngeal (Squamous Cell Carcinoma) | Candidate for Local Therapy (M0) | Primary Systemic Therapy or Post-Operative Systemic Therapy

High dose cisplatin\* with concurrent RT

## Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | First Line of Therapy (1<sup>st</sup> line)

Carboplatin, fluorouracil (5FU), and cetuximab (Erbixux)

Cisplatin, fluorouracil (5FU), and cetuximab (Erbixux)

## Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | Second and Subsequent Lines of Therapy (2<sup>nd</sup> line+)

Nivolumab (Opdivo)†

Paclitaxel<sup>23</sup>

## Nasopharynx | Candidate for Local Therapy (M0) | Primary Systemic Therapy

High dose cisplatin\* with concurrent RT

## Nasopharynx | Metastatic and Recurrent Disease | First and Subsequent Lines of Therapy (1<sup>st</sup> Line+)

Carboplatin

Cisplatin

Cisplatin‡ and gemcitabine (Gemzar)

Cisplatin‡ and paclitaxel

Fluorouracil (5FU)

Gemcitabine (Gemzar)

Gemcitabine (Gemzar) and vinorelbine (Navelbine)

Methotrexate

Paclitaxel

\*High dose cisplatin refers to dosing to achieve total dose of 200-300 mg/m<sup>2</sup> of cisplatin over the course of the radiotherapy. There are several different appropriate cisplatin schedules that may be used.

†Administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks

‡Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease

**Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.**

